MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-14-2023
Adamis Pharmaceuticals Corporation Income Statement 2011-2026 | ADMP
Annual Income Statement Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
18 M | 86.5 M | 61.3 M | 35.7 M | 121 M | 103 M | 54.3 M | 63.1 M | 39.8 M | 49.8 M | 58.2 M | 14.7 M |
Shares |
150 M | 144 M | 53.3 M | 53.3 M | 39.1 M | 28.3 M | 17.5 M | 13.3 M | 7.35 M | 5.86 M | 5.26 M | 3.75 M |
Historical Prices |
0.12 | 0.6 | 1.15 | 0.66 | 3.07 | 3.65 | 3.1 | 4.75 | 6.82 | 6.66 | 11.6 | 2.89 |
Net Income |
-26.5 M | -45.8 M | -49.4 M | -29.3 M | -39 M | -25.5 M | -19.4 M | -13.6 M | -8.16 M | -7.19 M | -4.92 M | -6.98 M |
Revenue |
4.76 M | 2.21 M | 16.5 M | 22.1 M | 15.1 M | 13.1 M | 6.47 M | - | - | - | - | - |
Cost of Revenue |
6.19 M | 6.87 M | 6.33 M | 15.5 M | 9.8 M | 7.42 M | - | - | - | - | - | - |
Gross Profit |
-1.43 M | -4.66 M | 1.63 M | 6.64 M | 5.29 M | 5.65 M | 1.62 M | - | - | - | - | - |
Operating Income |
-25.1 M | -32.1 M | -36.3 M | -29.4 M | -39.5 M | -24.8 M | -25.2 M | -13.9 M | -9.72 M | -3.22 M | -4.82 M | -6.24 M |
Interest Expense |
- | - | 4.92 K | 123 K | 158 K | 231 K | 214 K | - | 372 K | 2.33 M | 35.4 K | 744 K |
EBITDA |
-23.6 M | -30.6 M | -33.6 M | -26.1 M | -36.4 M | -21.6 M | -22.7 M | -12.9 M | -4.1 M | -3.22 M | -4.82 M | -6.23 M |
Operating Expenses |
- | - | 38.9 M | 35.7 M | 44.7 M | 30.3 M | 26.8 M | 13.9 M | 4.4 M | 3.22 M | 4.82 M | 6 M |
General and Administrative Expenses |
13.2 M | 16.1 M | - | 25.3 M | 25.9 M | 22.8 M | 17.1 M | 9.01 M | 3.39 M | 2.01 M | 2.9 M | 3.37 M |
All numbers in USD currency
Quarterly Income Statement Adamis Pharmaceuticals Corporation
| 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
7.07 M | 153 M | 2.14 M | 2.14 M | 150 M | 150 M | 150 M | 149 M | 149 M | 129 M | 93.8 M | 76 M | 73.8 M | 66.5 M | 61.8 M | 56.3 M | 47.5 M | 47.3 M | 47.3 M | 42.1 M | 33.4 M | 33.4 M | 33.4 M | 31.5 M | 26.2 M | 22.1 M | 22 M | 19.6 M | 15.4 M | 13.4 M | 13.4 M | 13.4 M | 13.4 M | 12.8 M | 10.7 M | 10.5 M | 10.5 M | 10.4 M | 6.74 M | 6.17 M | 6.16 M | 6.14 M | 5.81 M | 5.77 M | 97.7 M | 95.9 M | 91.9 M | 87.8 M | 85.9 M | 81.6 M |
Net Income |
-1.39 M | -8.94 M | - | -4.4 M | -8.4 M | -10.4 M | - | -12.4 M | -9.31 M | -15.4 M | - | -11.4 M | -12.9 M | -7.25 M | - | -7 M | -7.74 M | -8.89 M | - | -8.88 M | -9.7 M | -7.62 M | - | -6.77 M | -4.97 M | -5.77 M | - | -6.64 M | -5.71 M | -6.41 M | - | -3.15 M | -3.64 M | -3.14 M | - | -2.12 M | -2.88 M | -1.55 M | -5.53 M | -32 K | -1.07 M | - | -1.97 M | -5.56 M | -3.58 M | - | -991 K | -3.71 M | -2.72 M | - |
Revenue |
9.06 K | 1.45 M | - | 1.51 M | 39.8 K | 1.15 M | - | 760 K | 1.28 M | 1.39 M | - | 868 K | 3.93 M | 4.66 M | - | 5.9 M | 5.76 M | 4.91 M | - | 3.83 M | 3.92 M | 3.18 M | - | 3.39 M | 3.81 M | 3.04 M | - | 2.08 M | 1.93 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
338 K | 1.79 M | - | 1.65 M | 689 K | 1.46 M | - | 1.57 M | 1.8 M | 1.85 M | - | 1.41 M | 4.68 M | 3.69 M | - | 3.99 M | 3.67 M | 3.63 M | - | 2.3 M | 2.39 M | 2.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
-329 K | -335 K | - | -142 K | -649 K | -309 K | - | -806 K | -521 K | -452 K | - | -546 K | -757 K | 976 K | - | 1.91 M | 2.1 M | 1.28 M | - | 1.53 M | 1.53 M | 1.12 M | - | 1.3 M | 1.92 M | 1.37 M | - | 255 K | 582 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-3.27 M | -6.43 M | - | -4.63 M | -8.18 M | -7.91 M | - | -10.2 M | -7.65 M | -6.22 M | - | -5.5 M | -11.2 M | -10.3 M | - | -7.01 M | -7.75 M | -8.94 M | - | -8.91 M | -9.67 M | -7.61 M | - | -5.8 M | -4.92 M | -5.71 M | - | -6.58 M | -7.43 M | -6.02 M | - | -3.31 M | -3.53 M | -4.15 M | - | -1.94 M | -2.75 M | -1.71 M | -984 K | -957 K | -1.7 M | - | -748 K | -2.32 M | -1.58 M | - | -989 K | -3.68 M | -2.69 M | - |
Interest Expense |
29.5 K | -113 K | - | 278 K | - | -440 K | - | 1.86 K | 2.9 K | 1.88 K | - | 1.72 K | 32.9 K | 38.3 K | - | 21.9 K | 23 K | 24 K | - | 30.7 K | 51.4 K | 50.7 K | - | 52.6 K | 59.4 K | 67.5 K | - | 70.2 K | 72.4 K | - | - | - | - | - | - | 371 K | 226 K | 145 K | 5.3 M | 2.78 M | 3.18 M | - | 845 K | 1.72 M | 874 K | - | 2.61 K | 32.7 K | 30.1 K | - |
EBITDA |
-3.2 M | -6.32 M | - | -4.23 M | -7.81 M | -7.57 M | - | -9.85 M | -7.28 M | -5.89 M | - | -4.61 M | -10.4 M | -9.34 M | - | -6.19 M | -7.04 M | -8.1 M | - | -6.59 M | -8.13 M | -6.84 M | - | -3.48 M | -3.36 M | -4.93 M | - | -4.82 M | -7.28 M | -5.77 M | - | -2.56 M | -3.04 M | -3.9 M | - | -1.05 M | -2.45 M | -1.71 M | -984 K | -957 K | -1.7 M | - | -748 K | -2.32 M | -1.58 M | - | -989 K | -3.68 M | -2.69 M | - |
General and Administrative Expenses |
2.52 M | 4.78 M | - | 2.51 M | 4.21 M | 3.38 M | - | 4.79 M | 4.93 M | 3.52 M | - | 3.31 M | 5.65 M | 6.05 M | - | 5.3 M | 7 M | 8.02 M | - | 6.53 M | 6.36 M | 6.47 M | - | 5.75 M | 5.66 M | 5.57 M | - | 5.34 M | 4.58 M | 2.62 M | - | 2.13 M | 2.26 M | 2.79 M | - | 1.34 M | 1.01 M | 1.34 M | 776 K | 762 K | 1.28 M | - | 542 K | 1.59 M | 1.05 M | - | 807 K | 2.3 M | 1.49 M | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Adamis Pharmaceuticals Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Drug manufacturers industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | USA |
 |
Alimera Sciences
ALIM
|
- | - | $ 142 M | USA |
 |
Canopy Growth Corporation
CGC
|
$ 1.14 | -4.62 % | $ 123 M |  Canada |
 |
Cronos Group
CRON
|
$ 2.56 | 1.24 % | $ 1.35 B | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
$ 4.74 | 1.94 % | $ 66.6 M | USA |
 |
Catalent
CTLT
|
- | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
- | - | $ 28.9 M |  Irlanda |
 |
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
- | - | $ 36.6 M | USA |
 |
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
$ 11.08 | 0.82 % | $ 567 M | USA |
 |
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | USA |
 |
Evolus
EOLS
|
$ 5.05 | -2.88 % | $ 313 M | USA |
 |
Harrow Health
HROW
|
$ 47.49 | -0.86 % | $ 1.55 B | USA |
 |
China Pharma Holdings
CPHI
|
$ 1.25 | - | $ 21.8 M |  China |
 |
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
$ 1.62 | 0.62 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
$ 6.75 | -3.3 % | $ 2.46 B | Canada |
 |
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | Canada |
 |
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | USA |
 |
Sundial Growers
SNDL
|
$ 1.58 | -2.17 % | $ 3.37 M | Canada |
 |
Organogenesis Holdings
ORGO
|
$ 3.64 | -3.96 % | $ 479 M | USA |
 |
Pacira BioSciences
PCRX
|
$ 19.43 | 1.38 % | $ 899 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
$ 21.51 | 0.14 % | $ 2.05 B |  France |
 |
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
$ 15.06 | 0.2 % | $ 2.07 B | USA |
 |
Aurora Cannabis
ACB
|
$ 4.14 | -2.13 % | $ 86.3 M | Canada |
 |
ProPhase Labs
PRPH
|
- | - | $ 5.07 M | USA |
 |
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | USA |
 |
Rockwell Medical
RMTI
|
$ 1.22 | 27.44 % | $ 28.5 M | USA |
 |
Radius Health
RDUS
|
- | - | $ 1.42 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
$ 3.33 | 1.06 % | $ 4.13 M | USA |
 |
Relmada Therapeutics
RLMD
|
$ 3.93 | 5.01 % | $ 118 M | USA |
 |
OptiNose
OPTN
|
- | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
$ 12.04 | 4.88 % | $ 855 M | USA |
 |
Tilray
TLRY
|
$ 8.74 | -7.62 % | $ 5.4 B | Canada |
 |
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
$ 5.59 | 2.19 % | $ 228 M | USA |
 |
SCYNEXIS
SCYX
|
$ 0.65 | -0.68 % | $ 31.1 M | USA |
 |
Tricida
TCDA
|
- | - | $ 3.25 M | USA |
 |
Veru
VERU
|
$ 2.53 | -5.95 % | $ 341 M | USA |
 |
TherapeuticsMD
TXMD
|
$ 2.55 | 14.39 % | $ 26.6 M | USA |
 |
Viatris
VTRS
|
$ 12.66 | -1.59 % | $ 15.3 B | USA |
 |
Zomedica Corp.
ZOM
|
- | -0.21 % | $ 98 M | USA |
 |
cbdMD
YCBD
|
$ 0.83 | -9.94 % | $ 3.58 M | USA |